Prognostic significance of peripheral blood absolute lymphocyte count and derived neutrophil to lymphocyte ratio in patients with newly diagnosed extranodal natural killer/T-cell lymphoma

References

• Haverkos BM, Pan Z, Gru AA, et al. Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): an update on epidemiology, clinical presentation, and natural history in North American and European cases. Curr Hematol Malig Rep. 2016;11(6):514–527. doi:10.1007/s11899-016-0355-927778143
   PubMed Web of Science ®Google Scholar
• Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130. doi:10.1200/JCO.2008.16.455818626005
   PubMed Web of Science ®Google Scholar
• Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012;120(15):2973–2980. doi:10.1182/blood-2012-05-43146022919026
   PubMed Web of Science ®Google Scholar
• Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the international peripheral T-Cell lymphoma project. Blood. 2009;113(17):3931–3937. doi:10.1182/blood-2008-10-18525619029440
   PubMed Web of Science ®Google Scholar
• Tse E, Kwong YL. The diagnosis and management of NK/T-cell lymphomas. J Hematol Oncol. 2017;10(1):85. doi:10.1186/s13045-017-0452-928410601
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Suzuki R, Oguchi M. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type. Blood. 2018;131(23):2528–2540. doi:10.1182/blood-2017-12-79141829602763
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011;29(33):4410–4416. doi:10.1200/JCO.2011.35.628721990393
   PubMed Web of Science ®Google Scholar
• International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987–994.8141877
   PubMed Web of Science ®Google Scholar
• Kim SJ, Yoon DH, Jaccard A, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016;17(3):389–400. doi:10.1016/S1470-2045(15)00533-126873565
   PubMed Web of Science ®Google Scholar
• Mezquita L, Auclin E, Ferrara R, et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol. 2018;4(3):351–357. doi:10.1001/jamaoncol.2017.477129327044
   PubMed Web of Science ®Google Scholar
• Capone M, Giannarelli D, Mallardo D, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer. 2018;6(1):74. doi:10.1186/s40425-018-0383-130012216
   PubMed Web of Science ®Google Scholar
• Cox S, Hurt C, Grenader T, Mukherjee S, Bridgewater J, Crosby T. The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol. 2017;125(1):154–159. doi:10.1016/j.radonc.2017.08.02328893415
   PubMed Web of Science ®Google Scholar
• Song S, Li C, Li S, Gao H, Lan X, Xue Y. Derived neutrophil to lymphocyte ratio and monocyte to lymphocyte ratio may be better biomarkers for predicting overall survival of patients with advanced gastric cancer. Onco Targets Ther. 2017;10:3145–3154. doi:10.2147/OTT.S13803928706446
   PubMed Web of Science ®Google Scholar
• Templeton AJ, Rodriguez-Lescure A, Ruiz A, et al. Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy. Clin Transl Oncol. 2018;20(12):1548–1556. doi:10.1007/s12094-018-1885-5
   PubMed Web of Science ®Google Scholar
• Troppan K, Deutsch A, Gerger A, et al. The derived neutrophil to lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma. Br J Cancer. 2014;110(2):369–374. doi:10.1038/bjc.2013.76324357794
   PubMed Web of Science ®Google Scholar
• Quigley DA, Kristensen V. Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells. Mol Oncol. 2015;9(10):2054–2062. doi:10.1016/j.molonc.2015.10.00326607741
   PubMed Web of Science ®Google Scholar
• Feng F, Zheng G, Wang Q, et al. Low lymphocyte count and high monocyte count predicts poor prognosis of gastric cancer. BMC Gastroenterol. 2018;18(1):148. doi:10.1186/s12876-018-0863-230305076
   PubMedGoogle Scholar
• Joseph N, Dovedi SJ, Thompson C, et al. Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer. Ann Oncol. 2016;27(2):294–299. doi:10.1093/annonc/mdv54626578732
   PubMed Web of Science ®Google Scholar
• Milne K, Alexander C, Webb JR, et al. Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes. J Transl Med. 2012;10:33. doi:10.1186/1479-5876-10-23322369276
   PubMed Web of Science ®Google Scholar
• Suriu C, Akria L, Azoulay D, Shaoul E, Barhoum M, Braester A. Absolute lymphocyte count as a prognostic marker in newly diagnosed multiple myeloma patients. Int J Lab Hematol. 2016;38(3):e56–e59. doi:10.1111/ijlh.1248227018225
   PubMed Web of Science ®Google Scholar
• Jang JE, Kim YR, Kim SJ, et al. A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma. Eur J Cancer. 2016;57:127–135. doi:10.1016/j.ejca.2016.01.01626918738
   PubMed Web of Science ®Google Scholar
• Jia T, Zhang R, Zhu HY, et al. Prognostic significance of peripheral blood absolute monocyte count and lymphocyte to monocyte ratio in anaplastic large cell lymphoma. Cancer Biomark. 2018;22(4):807–813. doi:10.3233/CBM-18150529945349
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced hodgkin’s disease. International prognostic factors project on advanced hodgkin’s disease. N Engl J Med. 1998;339(21):1506–1514. doi:10.1056/NEJM1998111933921049819449
   PubMed Web of Science ®Google Scholar
• Galvez-Silva J, Maher OM, Park M, et al. Prognostic analysis of absolute lymphocyte and monocyte counts after autologous stem cell transplantation in children, adolescents, and young adults with refractory or relapsed Hodgkin lymphoma. Biol Blood Marrow Transplant. 2017;23(8):1276–1281. doi:10.1016/j.bbmt.2017.04.01328435146
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-64356926980727
   PubMed Web of Science ®Google Scholar
• Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer. 2012;107(4):695–699. doi:10.1038/bjc.2012.29222828611
   PubMed Web of Science ®Google Scholar
• Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–e503. doi:10.1016/S1470-2045(14)70263-325281468
   PubMed Web of Science ®Google Scholar
• Jacobson CA, LaCasce AS. Lymphoma: risk and response after solid organ transplant. Oncology (Williston Park). 2010;24(10):936–944.21138175
   PubMed Web of Science ®Google Scholar
• Farkas T, Muller J, Dj E, Csoka M, Gt K. Absolute Lymphocyte Count (ALC) after induction treatment predicts survival of pediatric patients with acute lymphoblastic leukemia. Pathol Oncol Res. 2017;23(4):889–897. doi:10.1007/s12253-017-0192-828138921
   PubMed Web of Science ®Google Scholar
• Kim Y, Kim SJ, Cheong JW, et al. Clinical impact of early recovery of peripheral blood absolute lymphocyte count after frontline autologous stem cell transplantation for diffuse large B-cell lymphoma. Hematol Oncol. 2017;35(4):465–471. doi:10.1002/hon.233227440113
   PubMed Web of Science ®Google Scholar
• Chen R, Wang C, Zhou Y, Wen B. Prognostic implications of circulating Epstein-Barr virus DNA for extranodal natural killer/T-cell lymphoma, nasal type: a meta-analysis. Cancer Manag Res. 2018;10:2183–2192. doi:10.2147/CMAR.S16216830050327
   PubMed Web of Science ®Google Scholar
• Li Q, Gao S, Ma J, et al. A lower ALC/AMC ratio is associated with poor prognosis of peripheral T-cell lymphoma-not otherwise specified. Leuk Res. 2018;73:5–11. doi:10.1016/j.leukres.2018.07.02030172956
   PubMed Web of Science ®Google Scholar
• Huang JJ, Jiang WQ, Lin TY, et al. Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Ann Oncol. 2011;22(1):149–155. doi:10.1093/annonc/mdq31420595450
   PubMed Web of Science ®Google Scholar
• Laird BJ, Fallon M, Hjermstad MJ, et al. Quality of life in patients with advanced cancer: differential association with performance status and systemic inflammatory response. J Clin Oncol. 2016;34(23):2769–2775. doi:10.1200/JCO.2015.65.774227354484
   PubMed Web of Science ®Google Scholar
• Ferrucci PF, Ascierto PA, Pigozzo J, et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol. 2016;27(4):732–738. doi:10.1093/annonc/mdw01626802161
   PubMed Web of Science ®Google Scholar
• Suzuki R, Takagi T, Hikichi T, et al. Derived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancer. Oncol Lett. 2016;11(5):3441–3445. doi:10.3892/ol.2016.438127123132
   PubMed Web of Science ®Google Scholar
• van Kessel KE, de Haan LM, Fransen van de Putte EE, et al. Elevated derived neutrophil-to-lymphocyte ratio corresponds with poor outcome in patients undergoing pre-operative chemotherapy in muscle-invasive bladder cancer. Bladder Cancer. 2016;2(3):351–360. doi:10.3233/BLC-16005527500202
   PubMed Web of Science ®Google Scholar
• Amato RJ, Flaherty A, Zhang Y, Ouyang F, Mohlere V. Clinical prognostic factors associated with outcome in patients with renal cell cancer with prior tyrosine kinase inhibitors or immunotherapy treated with everolimus. Urol Oncol. 2014;32(3):345–354. doi:10.1016/j.urolonc.2013.09.00824321256
   PubMed Web of Science ®Google Scholar
• Grenader T, Nash S, Plotkin Y, et al. Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies. Ann Oncol. 2015;26(9):1910–1916. doi:10.1093/annonc/mdv25326037798
   PubMed Web of Science ®Google Scholar
• Zhou X, Wang J, Xia J, et al. Evaluation of neutrophil-to-lymphocyte ratio in newly diagnosed patients receiving borte- zomib-based therapy for multiple myeloma. Cancer Biomark. 2018;22(1):43–48. doi:10.3233/CBM-17079529562497
   PubMed Web of Science ®Google Scholar
• Uz B. The prognostic value of the derived neutrophil-to-lymphocyte ratio in transplantation-ineligible patients with multiple myeloma. Acta Haematol. 2018;140(3):157–158. doi:10.1159/00049198830253407
   PubMed Web of Science ®Google Scholar